BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barutta F, Corbetta B, Bellini S, Guarrera S, Matullo G, Scandella M, Schalkwijk C, Stehouwer CD, Chaturvedi N, Soedamah-Muthu SS, Durazzo M, Gruden G. MicroRNA 146a is associated with diabetic complications in type 1 diabetic patients from the EURODIAB PCS. J Transl Med 2021;19:475. [PMID: 34823560 DOI: 10.1186/s12967-021-03142-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Ismail A, El-Mahdy HA, Eldeib MG, Doghish AS. miRNAs as cornerstones in diabetic microvascular complications. Mol Genet Metab 2023;138:106978. [PMID: 36565688 DOI: 10.1016/j.ymgme.2022.106978] [Reference Citation Analysis]
2 Xie Z, Xiao X. Novel biomarkers and therapeutic approaches for diabetic retinopathy and nephropathy: Recent progress and future perspectives. Front Endocrinol (Lausanne) 2022;13:1065856. [PMID: 36506068 DOI: 10.3389/fendo.2022.1065856] [Reference Citation Analysis]
3 De Felice B, Montanino C, Mallardo M, Babino G, Mattera E, Ragozzino G, Argenziano G, Daniele A, Nigro E. Circulating microRNAs in Hidradenitis Suppurativa. Genes 2022;13:1544. [DOI: 10.3390/genes13091544] [Reference Citation Analysis]
4 Li X, Venkatesh I, Villanueva V, Wei H, Geraghty T, Rajagopalan A, Helmuth RW, Altintas MM, Faridi HM, Gupta V. Podocyte-specific deletion of miR-146a increases podocyte injury and diabetic kidney disease. Front Med 2022;9. [DOI: 10.3389/fmed.2022.897188] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ren J, Zhang S, Pan Y, Jin M, Li J, Luo Y, Sun X, Li G. Diabetic retinopathy: Involved cells, biomarkers, and treatments. Front Pharmacol 2022;13:953691. [DOI: 10.3389/fphar.2022.953691] [Reference Citation Analysis]
6 Barutta F, Bellini S, Guarrera S, Matullo G, Schalkwijk C, Stehouwer CD, Chaturvedi N, Soedamah-Muthu SS, Durazzo M, Gruden G. Association of serum MicroRNA-145-5p levels with microvascular complications of type 1 Diabetes: The EURODIAB prospective complications study. Diabetes Res Clin Pract 2022;190:109987. [PMID: 35820565 DOI: 10.1016/j.diabres.2022.109987] [Reference Citation Analysis]
7 Pérez-Cremades D, Chen J, Assa C, Feinberg MW. MicroRNA-mediated control of myocardial infarction in diabetes. Trends Cardiovasc Med 2022:S1050-1738(22)00006-8. [PMID: 35051592 DOI: 10.1016/j.tcm.2022.01.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]